Pharma

At Healthcare 2030 in Washington, D.C., panelists highlighted debated challenges around interoperability, FHIR adoption and the need for industry-wide standards.

At an event in Washington, D.C., on Monday, DiMe released a thesis with what it says are four impact areas that are vital to pursue in digital medicine in the next five years.

The company says a single node is capable of processing approximately 22,000 genomes annually, triple the amount of earlier releases.

The company plans to expand partnerships with health plans and employers to provide more individuals with digital twin technology designed to improve metabolic health.

Define Ventures surveyed more than 40 executives from 15 of the top 20 pharma companies on the readiness of AI in healthcare, says Carolyn Magill, venture partner at the VC firm. A vast majority said AI is a priority in healthcare.

In a panel discussion, experts emphasized that AI must align with clinical workflows, reduce cognitive load, and support – not replace – clinicians.

The announcement comes the same week the pharma giant ended its collaboration with Hims & Hers to sell Wegovy, alleging the company engages in deceptive marketing and illegally sells copycat drugs.

The company offers an AI-enabled workflow automation platform for administrative tasks pertaining to specialty medications. 

Amino Health's navigation platform will provide health plans, third-party administrators, government agencies and health systems with tools to manage pharmacy and medical benefits.    

The AI-powered COPD care coordination tool uses EHR data and natural language processing to identify and manage high-risk patients.